Clinical Trial: Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489573) titled 'Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa' on March 18.

Brief Summary: This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).

Study Start Date: Aug. 21, 2026

Study Type: INTERVENTIONAL

Condition: Hidradenitis Suppurativa (HS)

Intervention: DRUG: Secukinumab

secukinumab 300 mg s.c. administered Q2W or Q4W

Recruitment Status: NOT_YET_RECRUITING

Spo...